Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
6:56 PM November 28, 2016Financing to be Used for the Development of a Portfolio of Treatments for Vascular Diseases and Ischemic Injuries Using Endonovo’s Immunotronics Platform LOS ANGELES, CA–ENDV, (Marketwired – Nov 28, 2016) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing
Read more